Who are the top 5 pharma companies?

Who Leads the Global Pharma Industry in 2026?

As of 2026, the pharmaceutical landscape continues to be shaped by a handful of powerhouse companies driving innovation, research, and global health solutions. At the top sits Johnson & Johnson, with a staggering revenue of $94.2 billion. Under CEO Joaquin Duato, the company maintains its dominance across pharmaceuticals, medical devices, and consumer health—though its recent strategic split has sharpened its focus on biopharma.

Coming in second is Swiss giant Roche, bringing in $78 billion. Known for its leadership in oncology and personalized medicine, Roche remains a key innovator, guided by CEO Dr. Thomas Schinecker. Close behind are Eli Lilly and Merck & Co (known as MSD outside the U.S.), with revenues of $65.2 billion and $65 billion, respectively. Eli Lilly’s surge has been fueled by breakthroughs in diabetes and weight-loss drugs, while Merck continues to ride the success of its cancer immunotherapy, Keytruda.

Pfizer, once in the global spotlight during the pandemic, holds steady with $62.6 billion in revenue. Though post-COVID demand has cooled, the company is reinventing itself with a strong pipeline in vaccines and rare diseases. Not far behind is AbbVie, clocking in at $61.2 billion, powered largely by the continued performance of Humira and new growth in immunology and oncology.

Completing the upper tier are AstraZeneca ($58.7 billion) and Novartis ($54.5 billion), both expanding aggressively in cardiovascular, respiratory, and gene therapy spaces. While rankings shift slightly year to year, these companies aren’t just leading in revenue—they’re shaping the future of medicine.